038290:KOSDAQ
Macrogen Inc
â‚©11,590.00
arrow_upward
+0.87%(+100.00) 1D
Oct 19, 3:30:30 PM GMT+9 · KRW
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 038290...
Open
â‚©11,430
High
â‚©11,680
Low
â‚©11,250
Mkt. cap
125.65B
Avg. vol.
15.64K
Volume
10.21K
Dividend
4.31%
Quarterly dividend
â‚©125
Ex-dividend date
Dec 27, 2024
P/E ratio
12.16
52-wk high
â‚©20,900
52-wk low
â‚©10,440
EPS
â‚©953
Shares outstanding
10.84M
No. of employees
473
Open
â‚©11,430
High
â‚©11,680
Low
â‚©11,250
Mkt. cap
125.65B
Avg. vol.
15.64K
Volume
10.21K
Dividend
4.31%
Quarterly dividend
â‚©125
Ex-dividend date
Dec 27, 2024
P/E ratio
12.16
52-wk high
â‚©20,900
52-wk low
â‚©10,440
EPS
â‚©953
Shares outstanding
10.84M
No. of employees
473
News stories
From web sources and news partners
HDFC Sky
·
31 minutes ago
Nasdaq Jumps 259 Points to 26,399 as Intel Surges 5.5% and AI Stocks Rebound After Brutal Selloff
TipRanks
·
24 minutes ago
Dow Jones Steady as AI Stocks Rebound from Selloff
TradingView
·
1 hour ago
The Dow Jones Index Opens 0.08% Lower
GuruFocus
·
58 minutes ago
Bank of America Securities Upgrades Dow Inc. (DOW) to Neutral on Rising Chemical Prices
Profile
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
About Macrogen Inc